The Advanced Therapies Treatment Centre (ATTC) Network’s recent report underscores the urgent need for rapid progress to maximize patient accessibility to advanced therapies. This report emphasizes key recommendations for advancing the advanced therapy sector, underlining the significance of data harmonization improvements and investments in workforce development to enhance patient access.
This comprehensive report draws from insights gathered at the ATTC Network’s UK Advanced Therapies Adoption Challenge event held in October. The event served as a platform for stakeholders to identify barriers and devise strategies to address challenges in the adoption of advanced therapies.
Advancing Adoption Strategies for Advanced Therapies
The primary call to action in the report revolves around establishing a novel, multi-stakeholder, cross-departmental advanced therapies task force. Central to this initiative are suggestions from experts advocating for bolstering the UK’s highly skilled research workforce and streamlining clinical trial approvals. These actions, as outlined in the report, are deemed crucial priorities to expedite progress and instill an ‘innovation-first’ mindset within the sector.
Outlined within the report are a series of recommendations aimed at addressing the challenges faced:
- Leveraging existing expertise to position the UK as a global leader in trialing and delivering these cutting-edge medicines.
- Recognizing the value of these therapies to ensure that UK patients can access the latest advancements in health technologies.
- Investing in workforce support and delivery infrastructure to enable widespread adoption of advanced therapies in the UK.
- Enhancing data utilization across the ecosystem to create a harmonized environment for these treatments.
Overcoming Barriers for Advancing Cell and Gene Therapies in the UK
The ATTC Network accentuates that despite significant advancements in developing new cell and gene therapies over the past five years to treat certain cancers and hereditary diseases, these innovative treatments encounter distinct obstacles compared to traditional medicines.
The report underscores the potential for the UK’s advanced therapy community to spearhead research, testing, and implementation of these groundbreaking therapies. However, substantial transformation is requisite to execute these ambitious strategies at scale, notes the organization.
Matthew Durdy, Chief Executive at the Cell and Gene Therapy Catapult, emphasizes the pivotal role of delivering advanced therapies at scale. Durdy asserts that ensuring patient access to transformative medicines upon approval will not only meet healthcare demands but also reduce costs and stimulate investments within the health system. This underscores the significance of implementing these recommendations to unlock the true potential of advanced therapies and revolutionize healthcare delivery.
Resource: European Pharmaceutical Review, December 08, 2023
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
